We are Sorry, This Page doesn't Exist

Weston company secures $10M in funding for drug to treat rare kidney disease
Incon Co., a publicly traded South Korean biotech investor, has given Weston-based Variant Pharmaceuticals $10 million in financing in exchange for equity ownership. The funding will be used to develop VAR 200 for the treatment of rare kidney disease .....»»
Biogen tanks as Alzheimer"s drug results disappoint
The experimental treatment slowed the disease, but not enough to meet investors' high expectations.....»»
Cambridge biotech startup grabs $65M to tackle liver disease
A newly launched biotech company has secured $65 million in financing as it seeks to develop the first-ever treatment for a disorder that its co-founder described as “the life being squeezed out of the liver.” Cambridge-based Akero Therapeutics is fo.....»»
Alzheimer’s Disease Symptoms Reversed in Flies by Balancing Enzymes
This finding could pave the wave for Alzheimer's treatment and biomarkers for early diagnosis......»»
IPO News This Week: Two Solid Offerings on Tap
The two IPOs on this week's calendar include one tech unicorn and a biotech working on a treatment from Alzheimer disease......»»
BioArctic - Full Year Report January - December 2018
STOCKHOLM, Feb. 14, 2019 /PRNewswire/ -- BioArctic's partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer's disease. AbbVie in-licensed the Parkinson po.....»»
Coty and Electronic Arts surge while Molson Coors dips
Stocks that moved substantially or traded heavily on Tuesday: Gilead Sciences Inc., down $2.22 to $65.40 A potential liver disease under development by the biotechnology company failed to meet its treatment goal in a key study......»»
Exclusive: Quietly, Gladstone founder"s new company plots unique attack on Alzheimer"s
In stealth mode, GABAeron is one of a growing number of companies zeroing in on new ways to stall, stop or cure Alzheimer's disease......»»
GSK, Merck KGaA partner to jointly develop cancer treatment M7824
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Gwyneth Paltrow and Netflix Sign Deal on Goop Docuseries
The show is set to premiere in the fall. Goop is getting the Netflix treatment. According to Variety, the lifestyle and wellness brand founded by actress Gwyneth Paltrow in 2008 is partnering with Netflix to develop a new docus.....»»
MeiraGTx partnering with Janssen to develop and market retinal disease therapy
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
The Daily Biotech Pulse: Roche Scraps Alzheimer"s Disease Trials, Amgen Issues Weak Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 29) read more.....»»
The Daily Biotech Pulse: Roche Scraps Alzheimer"s Disease Trials, Amgen Issues Weak Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The P.....»»
New research found a link between Alzheimer"s and gum disease bacteria, but there are other reasons gum disease is bad for your health
Jeff J Mitchell/Getty Images A new study found a .....»»
Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year
Non-alcoholic fatty liver disease, or NAFLD, is a disorder resulting from accumulation o.....»»
Could This Radical New Approach to Alzheimer’s Lead to a Breakthrough?
In a small lab in Jackson Hole, Wyo., 65-year-old Paul Cox believes he’s closing in on a treatment that might prevent Alzheimer’s disease. And ALS. And a host of other .....»»
Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data
Omeros Corporation (NASDAQ: OMER) shares are seeing buying interest Thursday following a clinical update on its lead human monoclonal antibody OMS721, which is being evaluated for IgA nephropathy. read more.....»»
Ultragenyx Wins Big in Blood Sugar Study
Ultragenyx Pharma shares made a handy gain to close out the week after the company announced positive results from its midstage trial for the treatment of glycogen storage disease type Ia......»»
A new type of breast cancer treatment could help stop the spread of a highly aggressive form of the disease
Eric Gaillard/Reut.....»»
Biogen doubles down on Alzheimer"s with new collaboration deal
On the eve of biotech's biggest conference, Biogen has announced two drug development deals — worth up to almost $500 million combined — targeting Alzheimer's disease and other neurological disorders. Biogen (Nasdaq: BIIB) said Friday that i.....»»